A federal advisory panel voted Thursday to relax rules on seven peptides, including BPC-157 and TB-500. The vote was slim. It is not binding. The FDA has given no clear statement on whether it will act on the guidance. The move came after weeks of open hearings. Wellness backers advocated aggressively for wider access. RFK Jr. was among them. Critics say these compounds have no real proof of safety or help for most uses. The call could change how the agency handles a part of the wellness market that is surging ahead. Patient groups are waiting to see if the agency takes up the plan. A representative for the agency offered no set date for a response. Critics argue the change would expand access to products that users favor. Safety voices warn that looser rules could allow poor oversight across a barely regulated market. The committee vote only sets up a possible shift, and the ultimate call rests with the federal regulator.